Translating cellular therapies from bench to bedside for amyotrophic lateral sclerosis

Personalized Medicine
Jonathan RileyNicholas M Boulis

Abstract

The last decade has witnessed an increasing number of biologic (e.g., cell- or viral vector-based) therapeutics supported by preclinical efficacy data for the treatment of afflictions to the CNS. While some international investigators have undertaken preliminary clinical safety studies, published literature indicate varying degrees of rigor with respect to study design and technical approach. To our knowledge, ours is the first group to have systematically generated preclinical validation data for a delivery approach and translated this into a Phase I trial attempting to covalidate the safety of a direct, targeted delivery approach, as well as a cell-based therapeutic. This article discusses the rationale for cell-based therapy in amyotrophic lateral sclerosis and several of the unique considerations encountered during this process.

References

Jul 1, 1995·Annals of Neurology·J D RothsteinR W Kuncl
Jan 31, 2002·Proceedings of the National Academy of Sciences of the United States of America·David S HowlandJeffrey D Rothstein
Sep 7, 2002·Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·Michael Swash
Sep 18, 2003·Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·Letizia MazziniEnrico Madon
Nov 30, 2004·Lancet·Letizia MazziniRiccardo Boccaletti
Feb 18, 2005·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Olle Lindvall, Anders Björklund
Aug 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·André RogatkoGary Hudes
Oct 13, 2005·Brain : a Journal of Neurology·F FéronA Mackay-Sim
Apr 6, 2006·Proceedings of the National Academy of Sciences of the United States of America·Hitoshi KikuchiSerge Przedborski
Oct 14, 2006·Transplantation·Leyan XuVassilis E Koliatsos
Jun 22, 2007·Journal of the Neurological Sciences·Letizia MazziniFranca Fagioli
Dec 13, 2007·Stereotactic and Functional Neurosurgery·Jonathan RileyNicholas M Boulis
Feb 26, 2008·Proceedings of the National Academy of Sciences of the United States of America·Christine Vande VeldeDon W Cleveland
Oct 22, 2008·Nature Neuroscience·Angelo C LeporeNicholas J Maragakis
Feb 5, 2009·Annals of Neurology·Jeffrey D Rothstein
Aug 7, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Eran PerlsonErika L F Holzbaur
Dec 3, 2009·The Journal of Cell Biology·Hristelina IlievaDon W Cleveland
Apr 13, 2010·Methods and Findings in Experimental and Clinical Pharmacology·R TerlindenT M Tzschentke
Apr 8, 2011·Neurosurgery·Jonathan P RileyNicholas M Boulis

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft
PCR

Related Concepts

Related Feeds

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.